China’s Hasten Biopharma acquires 14 products from Celltrion

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

China’s Hasten Biopharma acquires 14 products from Celltrion

INICIO/Noticias Farmacéuticas | Posted 10/09/2024 0 Post your comment

In July 2024, it was announced that China’s Hasten Biopharmaceutical has acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Korea’s Celltrion.

Celltrion is a biopharmaceutical company that has successfully developed and launched a number of biosimilars globally. These include Omlyclo (omalizumab), Celltrion's biosimilar of the reference product Xolair [1], Remsima (infliximab) which references Remicade [2], Herzuma (trastuzumab) which references Herceptin) [3], and Steqeyma (ustekinumab) which references Stelara [4].

According to the agreement, Hasten will also own the marketing authorisation holder (MAH) rights for products in eight countries and regions, including South Korea, Singapore, Thailand, Australia, and China Hong Kong.

The products include Actos, Edarbi, Nesina, Basen, and Blopress, all of which were acquired by Celltrion from Takeda in 2020 [5].

It is hoped that the deal will enrich Hasten's product pipeline across the countries and into regions outside mainland China. Combined with a more qualified global supply chain and a quality management system, the move is likely to pave the way for access to more high-quality products in the Pan-Asia Area. As the acquisition lays a solid foundation for the company's business expansion in Pan-Asia, Hasten is well positioned to become a leader in the chronic disease ecosystem.

Related articles
FDA BLA updates from Celltrion and Accord

FDA approves Zymfentra and advances for Yuflyma in the US

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Análisis del impacto presupuestario de la introducción de Rixathon en Chile para el linfoma no Hodgkin

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Análisis del impacto presupuestario de la introducción de Rixathon en Chile para el linfoma no Hodgkin

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of first omalizumab biosimilar Omlyclo [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-first-omalizumab-biosimilar-omlyclo
2. GaBI Online - Generics and Biosimilars Initiative. EMA approves first monoclonal antibody biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/EMA-approves-first-monoclonal-antibody-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. EC approval for trastuzumab biosimilar Herzuma [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/EC-approval-for-trastuzumab-biosimilar-Herzuma
4. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of four ustekinumab biosimilars: Eksunbi, Fymskina, Otulfi, Steqeyma [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-four-ustekinumab-biosimilars-eksunbi-fymskina-otulfi-steqeyma
5. GaBI Online - Generics and Biosimilars Initiative. Celltrion: Takeda acquisitions and new plant development [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Sep 10]. Available from: www.gabionline.net/pharma-news/Celltrion-Takeda-acquisitions-and-new-plant-development

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.